HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

California animal testing

This article was originally published in The Rose Sheet

Executive Summary

Senator Jack O'Connell (D-Santa Barbara) introduces SB 777 Feb 24 to prohibit manufacturers from using the ocular or skin irritant assays on animals to test cosmetics or household products. The tests are "unnecessary for the testing of cosmetics," and are "therefore cruel to animals," the bill states. SB 777 also encourages the use of alternatives to in vivo tests "whenever possible." Any violation will result in a $2,000 fine. The bill had been introduced in two prior sessions, but was vetoed by Republican governors. With the recent appointment of Democrat Gray Davis to the governor's mansion and increased education about the subject, the bill could have an increased chance of passing this session
Advertisement

Related Content

California Non-Animal Testing Revised Bill To Be Introduced In February
California Non-Animal Testing Revised Bill To Be Introduced In February
Advertisement
UsernamePublicRestriction

Register

RS006380

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel